Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Summary

The purpose of this study is to evaluate the safety and tolerability of Palbociclib in combination with investigational (experimental) drug, CPX-351 and evaluate the efficacy of Palbociclib in combination with chemotherapy as measured by overall response rate (ORR), i.e. complete response (CR) and CR with incomplete blood count recovery (CRi) by 2003 IWG criteria.

Timeline

Start

2019-06-06

Primary completion

2024-01-24

Completion

2024-01-24

Drugs

Indications